HCPLive Network

Role of Omega-3 in Secondary Prevention of CVD Questioned

Thursday, April 12 (HealthDay News) -- Sang Mi Kwak, M.D., from the Center for Cancer Prevention and Detection in Ilsan, South Korea, and colleagues conducted a meta-analysis of randomized, double-blind, placebo-controlled trials to investigate the efficacy of eicosapentaenoic acid and docosahexaenoic acid in the secondary prevention of CVD. The final analyses included 14 trials involving 20,485 patients with a history of CVD.

The researchers found that consuming omega-3 fatty acid supplements was not associated with a significantly reduced risk of overall cardiovascular events (relative risk [RR], 0.99), or with all-cause mortality, sudden cardiac death, myocardial infarction, congestive heart failure, or transient ischemic attack and stroke. The slight reduction in cardiovascular death (RR, 0.91) did not persist when a methodologically flawed study was excluded from the analyses. No significant preventive effect was seen in any of the subgroups analyzed.

"Our meta-analysis showed insufficient evidence of a secondary preventive effect of omega-3 fatty acid supplements against overall cardiovascular events among patients with a history of cardiovascular disease," the authors write.

The majority of the trials included in the study were funded by pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

For patients with a history of cardiovascular disease, evidence is lacking for a secondary preventive effect of omega-3 fatty acid supplements, according to a meta-analysis published online April 9 in the Archives of Internal Medicine.

Copyright © 2012 HealthDay. All rights reserved.


Further Reading
Competition between medical practices helps keep health care costs lower, according to a study published in the Oct. 22/29 issue of the Journal of the American Medical Association.
Frequent readmissions and high inpatient costs are seen among older survivors of in-hospital cardiac arrest, according to a study published online Oct. 28 in Circulation: Cardiovascular Quality and Outcomes
The new Idiopathic Pulmonary Fibrosis medications that were recently approved will help with treatment for patients but are not a cure for the condition.
More Reading